These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 8662133)

  • 1. Potential strategies for inflammatory mediator manipulation: retrospect and prospect.
    Fisher CJ; Zheng Y
    World J Surg; 1996 May; 20(4):447-53. PubMed ID: 8662133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models as the basis of pharmacologic intervention in trauma and sepsis patients.
    Redl H; Schlag G; Bahrami S; Yao YM
    World J Surg; 1996 May; 20(4):487-92. PubMed ID: 8662140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Problems and perspective approaches to correction of mediator response in sepsis].
    Mironov PI; Rudnov VA
    Anesteziol Reanimatol; 1999; (3):54-9. PubMed ID: 10458039
    [No Abstract]   [Full Text] [Related]  

  • 4. Endotoxin, sepsis, and the primrose path.
    O'Reilly M; Newcomb DE; Remick D
    Shock; 1999 Dec; 12(6):411-20. PubMed ID: 10588508
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolism of sepsis and multiple organ failure.
    Michie HR
    World J Surg; 1996 May; 20(4):460-4. PubMed ID: 8662135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acute septic cardiomyopathy].
    Müller-Werdan U
    Internist (Berl); 1998 May; 39(5):467-78. PubMed ID: 9647981
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pathophysiology and therapy of sepsis-associated coagulation disorders].
    Knöbl P
    Wien Med Wochenschr; 2002; 152(21-22):559-63. PubMed ID: 12506679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues.
    Fry DE
    Am Surg; 2012 Jan; 78(1):1-8. PubMed ID: 22273282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology, pathophysiology and clinical presentation of gram-negative sepsis.
    Hazinski MF; Iberti TJ; MacIntyre NR; Parker MM; Tribett D; Prion S; Chmel H
    Am J Crit Care; 1993 May; 2(3):224-35; quiz 236-7. PubMed ID: 8364674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine modifiers: pipe dream or reality?
    Abraham E
    Chest; 1998 Mar; 113(3 Suppl):224S-227S. PubMed ID: 9515897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal antibodies against inflammatory mediators for the treatment of patients with sepsis].
    Matsubara T
    Nihon Rinsho; 2002 Mar; 60(3):578-84. PubMed ID: 11904976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials of new and novel therapeutic agents.
    Baue AE; Durham RM; Mazuski JE
    World J Surg; 1996 May; 20(4):493-8. PubMed ID: 8662141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical infections: blocking the mediator cascade responsible for sepsis and septic shock.
    Fink MP
    Curr Opin Gen Surg; 1993; ():19-25. PubMed ID: 7583965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense?
    van der Poll T; Lowry SF
    Shock; 1995 Jan; 3(1):1-12. PubMed ID: 7850574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MODS/SIRS: result of an overwhelming inflammatory response?
    Goris RJ
    World J Surg; 1996 May; 20(4):418-21. PubMed ID: 8662124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic plasma exchange in severe sepsis or septic shock.
    Kes P
    Acta Med Croatica; 1998; 52(2):127-32. PubMed ID: 9682501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targets for sepsis therapies: tumor necrosis factor versus interleukin-1.
    Russell DA; Thompson RC
    Curr Opin Biotechnol; 1993 Dec; 4(6):714-21. PubMed ID: 7764470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Physiopathology of severe sepsis].
    Caille V; Bossi P; Grimaldi D; Vieillard-Baro A
    Presse Med; 2004 Feb; 33(4):256-61; discussion 269. PubMed ID: 15029017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapies for sepsis and septic shock.
    Oh HM
    Ann Acad Med Singap; 1998 Sep; 27(5):738-43. PubMed ID: 9919353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.